Rituxan

Latest stories

6d
The Globe and Mail
Novartis to buy multiple sclerosis drug from GlaxoNovartis bolstered its portfolio of multiple sclerosis treatments on Friday by
Novartis to buy multiple sclerosis drug from Glaxo
The Globe and Mail / Posted 6 days ago
Novartis bolstered its portfolio of multiple sclerosis treatments on Friday by agreeing to buy an experimental drug from GlaxoSmithKline for up to $1-billion, the company said. Novartis, the Swiss pharmaceutical giant, acquired the rights this year... Read more
10 related stories
15d
PharmaceuticalOnline
Could Birth Of “Big Generic” Be Foreshadowing “Big Biosimilar”The past few weeks, the generics market has seen several players jump ship and
Could Birth Of “Big Generic” Be Foreshadowing “Big Biosimilar”
PharmaceuticalOnline / Posted 15 days ago
The past few weeks, the generics market has seen several players jump ship and one company grow significantly — and to some, alarmingly — larger. First to take the plunge was Allergan, which sold off its portfolio of generic drugs to goliath Teva for... Read more
20d
Reuters
Pfizer, Bristol revive cancer drugs that rev up immune systemThe Pfizer logo is seen at their world headquarters in New York April 28, 2014.
Pfizer, Bristol revive cancer drugs that rev up immune system
Reuters / Posted 20 days ago
The Pfizer logo is seen at their world headquarters in New York April 28, 2014. NEW YORK Some of the most heralded new cancer drugs fight the disease by removing brakes on the immune system. Now a few leading drugmakers are paying attention to a... Read more
2 related stories
20d
Channel NewsAsia
Pfizer, Bristol revive cancer drugs that rev up immune systemNEW YORK: Some of the most heralded new cancer drugs fight the disease by remov
Pfizer, Bristol revive cancer drugs that rev up immune system
Channel NewsAsia / Posted 20 days ago
NEW YORK: Some of the most heralded new cancer drugs fight the disease by removing brakes on the immune system. Now a few leading drugmakers are paying attention to a second, opposing force: medicines that accelerate the immune system's... Read more
2 related stories
29d
Fulda Free Press
Fulda Free PressOn June 3, 2014 I went to the Avera Cancer Prairie Center and met Dr. Galal. Th
Fulda Free Press
Fulda Free Press / Posted 29 days ago
On June 3, 2014 I went to the Avera Cancer Prairie Center and met Dr. Galal. They did blood work immediately. We discussed with Dr. Galal about my weight loss, nightly sweats and always tired. Dr. Galal read my blood work and discovered an enlarged... Read more
29d
PharmaceuticalOnline
New Teva AstraZeneca Deals To Bolster Emerging Biosimilar MarketAfter this week, it looks like there will be a few big players advancing in the
New Teva AstraZeneca Deals To Bolster Emerging Biosimilar Market
PharmaceuticalOnline / Posted 29 days ago
After this week, it looks like there will be a few big players advancing in the biosimilar market. For those concerned about what a Teva-Mylan acquisition deal would do to the generics industry, recent action on behalf of Teva finally put those fears... Read more
1m
Morningstar
Biogen's Drop Looks Like OverreactionBiogen reported disappointing second-quarter results and lowered its guidance f
Biogen's Drop Looks Like Overreaction
Morningstar / Posted a month ago
Biogen reported disappointing second-quarter results and lowered its guidance for the full year, largely because of lower demand for Tecfidera in the United States and a weaker pricing environment in Europe. We think the competitive landscape in... Read more
m
Channel NewsAsia
AstraZeneca chases biosimilar Avastin drug with Japanese groupLONDON: AstraZeneca is dipping its toe in the biosimilars market, as a way to m
AstraZeneca chases biosimilar Avastin drug with Japanese group
Channel NewsAsia / Posted 1 months ago
LONDON: AstraZeneca is dipping its toe in the biosimilars market, as a way to make future cancer drug cocktails more affordable, by linking with a Japanese group to develop a copy of Roche's blockbuster medicine Avastin. Its new 50/50 joint venture... Read more

People in this news